4D Molecular Therapeutics (FDMT) News Today $4.10 -0.22 (-4.99%) Closing price 03:54 PM EasternExtended Trading$4.22 +0.13 (+3.17%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period 4D Molecular Therapeutics Inc News (FDMT) - Investing.com1 hour ago | investing.comChardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)July 3 at 8:27 AM | marketbeat.com4D Molecular to layoff about 25% of workforceJuly 2 at 6:58 PM | msn.com4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage ExecutionJuly 2 at 4:05 PM | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of "Moderate Buy" by BrokeragesJune 30 at 3:31 AM | americanbankingnews.com4D Molecular Therapeutics' (FDMT) "Sell (E+)" Rating Reaffirmed at Weiss RatingsJune 28, 2025 | americanbankingnews.comWeiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)June 28, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 25, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss RatingsJune 12, 2025 | marketbeat.comCantor Fitzgerald Estimates FDMT FY2026 EarningsJune 11, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Two Sigma Advisers LPJune 3, 2025 | marketbeat.comTwo Sigma Investments LP Acquires 208,021 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)June 3, 2025 | marketbeat.comBank of America Corp DE Buys 127,885 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)June 3, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 1, 2025 | marketbeat.comVoloridge Investment Management LLC Reduces Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 31, 2025 | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comMillennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 28, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss RatingsMay 28, 2025 | marketbeat.com4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progressMay 27, 2025 | investing.comDeutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 26, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 26, 2025 | marketbeat.comJane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 23, 2025 | marketbeat.comVR Adviser LLC Decreases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 22, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Janus Henderson Group PLCMay 19, 2025 | marketbeat.comDimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 19, 2025 | marketbeat.com4DMT Announces New Employment Inducement GrantsMay 16, 2025 | globenewswire.comCantor Fitzgerald Has Negative View of FDMT FY2025 EarningsMay 16, 2025 | marketbeat.comHC Wainwright Analysts Raise Earnings Estimates for FDMTMay 16, 2025 | marketbeat.comCubist Systematic Strategies LLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 14, 2025 | marketbeat.comAlgert Global LLC Acquires 103,342 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 13, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (E+)" Rating at Weiss RatingsMay 12, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given New $38.00 Price Target at BarclaysMay 11, 2025 | marketbeat.comRaymond James Financial Inc. Invests $629,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 10, 2025 | marketbeat.com4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesMay 9, 2025 | finance.yahoo.com4D Molecular Therapeutics, Inc.: 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesMay 9, 2025 | finanznachrichten.deDeep Track Capital LP Decreases Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 9, 2025 | marketbeat.com4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesMay 8, 2025 | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 8, 2025 | marketbeat.comMarshall Wace LLP Decreases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 7, 2025 | marketbeat.comBVF Inc. IL Decreases Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 6, 2025 | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesMay 5, 2025 | globenewswire.com4D Molecular Therapeutics Receives FDA RMAT Designation for 4D-150 in Diabetic Macular EdemaMay 3, 2025 | nasdaq.comRA Capital Management L.P. Lowers Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 3, 2025 | marketbeat.com4D Molecular Therapeutics (FDMT) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comFDA awards RMAT status to 4DMT diabetic macular oedema therapyMay 2, 2025 | finance.yahoo.com4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEMay 1, 2025 | globenewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss RatingsApril 27, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)April 21, 2025 | marketbeat.comVanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)April 20, 2025 | marketbeat.comEquities Analysts Offer Predictions for FDMT FY2026 EarningsApril 19, 2025 | marketbeat.com Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address FDMT Media Mentions By Week FDMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.150.54▲Average Medical News Sentiment FDMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼94▲FDMT Articles Average Week Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SION News GYRE News PHAT News ANAB News IMTX News TRVI News NUVB News DAWN News GHRS News STOK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
